Reactividad cruzada de preparados de insulina recombinante con 2 inmunoanálisis comerciales para determinación de insulina en sangre

Abstract

IntroductionThe large variability in cross-reactivities of recombinant insulin preparations with different commercial assays is noteworthy. It is imperative to know which recombinant insulin preparations a method can detect and which ones it cannot, to interpret certain laboratory results. ObjectiveTo asses the cross-reactivity of soluble insulin, insulin NPH, glulisina and detemir with insulin inmunoassays Elecsys/E170 (Roche) and Architect (Abbott). Material and methodsSolutions of glulisine, detemir, soluble insulin and insulin NPH (20 - 1000 mU/L) were prepared and analized with insulin inmunoassays Elecsys/E170 (Roche) and Architect (Abbott). The cross-reactivity percentage was calculated for each solution. ResultsWith Elecsys/E170, the cross-reactivity of glulisine and detemir was < 5% for all solutions. The cross-reactivity of soluble insulin was 120% and insulin NPH 106%.With Architect, the cross-reactivity of glulisine was 12,6%; detemir 130% for 20 mU/L and >240% for 100 mU/L; soluble insulin 99% and insulin NPH 153%. ConclusionsElecsys/E170 detects both preparations of insulin of human sequence but it does not detect gluisine nor detemir. Architect detects both preparations of insulin of human sequence and detemir; for gluisine the average of cross-reactivity is 12,6%.Colaboration between laboratories employing different immunoassays may be useful to throw light on some hypoglycemia profiles, where overdose or misadministration of insulin preparations is suspected.